309 related articles for article (PubMed ID: 29348486)
1. Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.
Kim RD; Alberts SR; Peña C; Genvresse I; Ajavon-Hartmann A; Xia C; Kelly A; Grilley-Olson JE
Br J Cancer; 2018 Feb; 118(4):462-470. PubMed ID: 29348486
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
[TBL] [Abstract][Full Text] [Related]
3. A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.
Bridgewater J; Lopes A; Beare S; Duggan M; Lee D; Ricamara M; McEntee D; Sukumaran A; Wasan H; Valle JW
BMC Cancer; 2016 Feb; 16():153. PubMed ID: 26912134
[TBL] [Abstract][Full Text] [Related]
4. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Patnaik A; Appleman LJ; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Weiss GJ; Sachdev JC; Chadha M; Fulk M; Ejadi S; Mountz JM; Lotze MT; Toledo FG; Chu E; Jeffers M; Peña C; Xia C; Reif S; Genvresse I; Ramanathan RK
Ann Oncol; 2016 Oct; 27(10):1928-40. PubMed ID: 27672108
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.
Watanabe A; Kida M; Miyazawa S; Iwai T; Okuwaki K; Kaneko T; Yamauchi H; Takezawa M; Imaizumi H; Koizumi W
World J Gastroenterol; 2015 May; 21(19):5979-84. PubMed ID: 26019463
[TBL] [Abstract][Full Text] [Related]
6. Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers.
Lowery MA; Bradley M; Chou JF; Capanu M; Gerst S; Harding JJ; Dika IE; Berger M; Zehir A; Ptashkin R; Wong P; Rasalan-Ho T; Yu KH; Cercek A; Morgono E; Salehi E; Valentino E; Hollywood E; O'Reilly EM; Abou-Alfa GK
Clin Cancer Res; 2019 Feb; 25(3):937-945. PubMed ID: 30563938
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004).
Toyoda M; Ajiki T; Fujiwara Y; Nagano H; Kobayashi S; Sakai D; Hatano E; Kanai M; Nakamori S; Miyamoto A; Tsuji A; Kaihara S; Ikoma H; Takemura S; Toyokawa H; Terajima H; Morita S; Ioka T
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1295-301. PubMed ID: 24614947
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
Shoji H; Morizane C; Sakamoto Y; Kondo S; Ueno H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
Jpn J Clin Oncol; 2016 Feb; 46(2):132-7. PubMed ID: 26685318
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
[TBL] [Abstract][Full Text] [Related]
11. Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.
Phelip JM; Desrame J; Edeline J; Barbier E; Terrebonne E; Michel P; Perrier H; Dahan L; Bourgeois V; Akouz FK; Soularue E; Ly VL; Molin Y; Lecomte T; Ghiringhelli F; Coriat R; Louafi S; Neuzillet C; Manfredi S; Malka D;
J Clin Oncol; 2022 Jan; 40(3):262-271. PubMed ID: 34662180
[TBL] [Abstract][Full Text] [Related]
12. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C; Okusaka T; Mizusawa J; Katayama H; Ueno M; Ikeda M; Ozaka M; Okano N; Sugimori K; Fukutomi A; Hara H; Mizuno N; Yanagimoto H; Wada K; Tobimatsu K; Yane K; Nakamori S; Yamaguchi H; Asagi A; Yukisawa S; Kojima Y; Kawabe K; Kawamoto Y; Sugimoto R; Iwai T; Nakamura K; Miyakawa H; Yamashita T; Hosokawa A; Ioka T; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Ann Oncol; 2019 Dec; 30(12):1950-1958. PubMed ID: 31566666
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
Goff LW; Cardin DB; Whisenant JG; Du L; Koyama T; Dahlman KB; Salaria SN; Young RT; Ciombor KK; Gilbert J; Smith SJ; Chan E; Berlin J
Invest New Drugs; 2017 Feb; 35(1):95-104. PubMed ID: 27853997
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
[TBL] [Abstract][Full Text] [Related]
15. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.
Vogel A; Kasper S; Bitzer M; Block A; Sinn M; Schulze-Bergkamen H; Moehler M; Pfarr N; Endris V; Goeppert B; Merx K; Schnoy E; Siveke JT; Michl P; Waldschmidt D; Kuhlmann J; Geissler M; Kahl C; Evenkamp R; Schmidt T; Kuhlmann A; Weichert W; Kubicka S
Eur J Cancer; 2018 Mar; 92():11-19. PubMed ID: 29413685
[TBL] [Abstract][Full Text] [Related]
16. Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.
Leijen S; van Geel RM; Pavlick AC; Tibes R; Rosen L; Razak AR; Lam R; Demuth T; Rose S; Lee MA; Freshwater T; Shumway S; Liang LW; Oza AM; Schellens JH; Shapiro GI
J Clin Oncol; 2016 Dec; 34(36):4371-4380. PubMed ID: 27601554
[TBL] [Abstract][Full Text] [Related]
17. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
[TBL] [Abstract][Full Text] [Related]
18. TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer.
Ferraro D; Goldstein D; O'Connell RL; Zalcberg JR; Sjoquist KM; Tebbutt NC; Grimison P; McLachlan S; Lipton LL; Vasey P; Gebski VJ; Aiken C; Cronk M; Ng S; Karapetis CS; Shannon J;
Cancer Chemother Pharmacol; 2016 Aug; 78(2):361-7. PubMed ID: 27335026
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.
Angevin E; Cassier PA; Italiano A; Gonçalves A; Gazzah A; Terret C; Toulmonde M; Gravis G; Varga A; Parlavecchio C; Paci A; Poinsignon V; Soria JC; Drubay D; Hollebecque A
Eur J Cancer; 2017 Sep; 83():194-202. PubMed ID: 28750271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
